Our approach to clinical development is deeply rooted in our understanding of activin biology and where we believe bimagrumab will have the greatest benefit. Our initial treatment areas are obesity and heart failure with additional indications to follow.
Heart Failure in Obesity
1 Heart failure with preserved ejection fraction
2 Heart failure with reduced ejection fraction
Bimagrumab has been evaluated in 20+ clinical trials